{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:14:45Z","timestamp":1790154885883,"version":"4.0.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Japanese encephalitis (JE) is a major public health concern in Asia and poses a small but potentially fatal threat to travelers from nonendemic countries, including children. No JE vaccine for pediatric use has been available in Europe and the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Age-stratified cohorts of children between 2 months and 17 years received 2 doses of Vero cell-derived inactivated JE virus vaccine (IXIARO; Valneva Austria GmbH, Vienna, Austria) administered 28 days apart [&lt;3 years, 0.25\u2009mL (half adult dose); \u22653 years, 0.5\u2009mL (full adult dose)]. Immunogenicity endpoints were seroconversion rate, 4-fold increase in JE neutralizing antibody titer and geometric mean titer assessed 56 days and 7 months after the first vaccination in 496 subjects of the intent-to-treat population. The immune response to JE virus at both time points was also analyzed according to prevaccination JE virus and dengue virus serostatus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At day 56, seroconversion was attained in \u226599.2% of subjects with age-appropriate dosing, 4-fold increases in titer were reported for 77.4%\u2013100% in various age groups, and geometric mean titers ranged from 176 to 687, with younger children having the strongest immune response. At month 7, seroconversion was maintained in 85.5%\u2013100% of subjects. Pre-existing JE virus immunity did not impact on immune response at day 56; however, it led to a better persistence of protective antibody titers at month 7.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>IXIARO is highly immunogenic at both doses tested in the pediatric population, leading to protective antibody titers at day 56 in &gt;99% of subjects who received the age-appropriate dose.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001615","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T06:56:09Z","timestamp":1492757769000},"page":"898-904","source":"Crossref","is-referenced-by-count":18,"title":["Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region"],"prefix":"10.1097","volume":"36","author":[{"given":"Katrin L.","family":"Dubischar","sequence":"first","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kadlecek","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sablan","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa Fay","family":"Borja-Tabora","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvacion","family":"Gatchalian","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Kiermayr","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spruth","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Westritschnig","sequence":"additional","affiliation":[{"name":"Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis.","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review.","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1371\/journal.pntd.0000114","article-title":"Measuring the burden of neglected tropical diseases: the global burden of disease framework.","volume":"1","author":"Mathers","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"R4-20230912","first-page":"325","article-title":"Japanese encephalitis vaccines.","volume":"81","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"issue":"RR-1","key":"R5-20230912","first-page":"1","article-title":"Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/INF.0000000000001623","article-title":"Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, Phase 3 study.","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.ento.54.110807.090510","article-title":"Ecology and geographical expansion of Japanese encephalitis virus.","volume":"54","author":"van den Hurk","year":"2009","journal-title":"Annu Rev Entomol"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973-2008.","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"R9-20230912","first-page":"276","article-title":"Japanese encephalitis in two children\u2013United States, 2010.","volume":"2011","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1586\/erv.12.100","article-title":"Vaccinating against Japanese encephalitis virus: what have we learned from recent clinical trials?","volume":"11","author":"Dubischar-Kastner","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51.","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines.","volume":"319","author":"Hoke","year":"1988","journal-title":"N Engl J Med"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age.","volume":"28","author":"Kaltenb\u00f6ck","year":"2010","journal-title":"Vaccine"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2180-2-9","article-title":"Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses.","volume":"2","author":"Cardosa","year":"2002","journal-title":"BMC Microbiol"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1501.080311","article-title":"Past, present, and future of Japanese encephalitis.","volume":"15","author":"Erlanger","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"suppl 3","key":"R22-20230912","first-page":"136","article-title":"Use of IgM-capture ELISA for confirmation of Japanese encephalitis infections in the Philippines.","volume":"37","author":"Natividad","year":"2006","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R23-20230912","first-page":"39","article-title":"The neurologic features of Japanese encephalitis in the Philippines.","volume":"19","author":"San Luis","year":"1990","journal-title":"Phil J Microbiol Infect Dis"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/590008","article-title":"The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central Sarawak, Malaysia, 1997-2005.","volume":"47","author":"Ooi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004.","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe.","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled phase 3 study.","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"e0003630","DOI":"10.1371\/journal.pntd.0003630","article-title":"Epidemiology of Japanese encephalitis in the Philippines: a systematic review.","volume":"9","author":"Lopez","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.vaccine.2010.01.008","article-title":"Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program.","volume":"28","author":"Konishi","year":"2010","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201709000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:00:58Z","timestamp":1694559658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201709000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001615","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}